ClinicalTrials.gg
RecruitingNCT04965766ICARUS BREASTUpdated Dec 23, 2025

Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer

A Phase 2 interventional study of U3-1402 in Metastatic Breast Cancer and Advanced Breast Cancer, sponsored by Gustave Roussy, Cancer Campus, Grand Paris. Recruiting at 11 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-23.

Sponsored by Gustave Roussy, Cancer Campus, Grand Paris · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2021; still recruiting 5 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
139
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies testing patritumab deruxtecan in Breast Neoplasms — 7 open to participants now, 9 under way, 1 of them phase 3. patritumab deruxtecan · Breast Neoplasms.

Planned enrollment
8th of 12
139 · median 167
Started
2021
with 1 other
Phase 2
6 of 12
3 open now
Registered
4th of 12
by date
Lead sponsor
2 of 12
Gustave Roussy, Cancer Campus, Grand Paris

Among the 12 studies testing patritumab deruxtecan in Breast Neoplasms, this one is the 8th largest by planned enrollment, is one of 2 that started in 2021, is one of 6 in phase 2, and was the 4th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

7 of the 12 studies testing patritumab deruxtecan in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About patritumab deruxtecan

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing patritumab deruxtecan in Breast Neoplasms, or all of them as a file.
02

Study summary

This study aims to evaluate the efficacy and safety of U3-1402 in participants with advanced breast cancer (ABC). Participants have to be hormone-receptor positive (HR+) and have to be resistant to endocrine therapy and cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors. Participants may have received multiple lines of endocrine therapy with or without targeted therapies and must have received only one line of chemotherapy for ABC.

Moreover, the immune effects, the predictors of resistance and response to treatment, the effect of the chemotherapy on deoxyribonucleic acid (DNA) replication will be assessed and will help identify the subgroups that will mostly benefit from the treatment. The pharmacokinetics of the product and the anti-drug antibody (ADA) will be also evaluated.

A total of 99 participants are planned to be treated in the study. Participants will receive, every three weeks, a dose of U3-1402 equivalent to 5.6 mg/kg of body weight until progression or until unacceptable toxicity.

Tumor evaluation will be performed every six weeks by the mean of a computed tomography for the thorax, abdomen and pelvis (TAP CT-scan) or a magnetic resonance imaging (MRI). Brain and/or bone CT scans will be also performed throughout the study for participants with brain and/or bone metastasis. A PET scan combined with contrast enhanced CT scan can replace all the above-mentioned imaging if performed at baseline considering that the same imaging technique should be used throughout the study.

The safety of the product will be assessed at each cycle, through complete clinical exams, biological tests, electrocardiograms (ECGs), cardiac echographies (ECHOs) and through the collection of ongoing toxicities or adverse events.

03

Conditions studied

  • Metastatic Breast Cancer
  • Advanced Breast Cancer

Browse trials for

Keywords

  • Metastatic breast cancer
  • Advanced breast cancer
  • Unresectable breast cancer
  • HER2- Breast Cancer
  • Hormone-receptor positive breast cancer
  • HR+ breast cancer
  • Antibody drug conjugate
  • ADC
  • Patritumab deruxtecan
  • U3-1402
  • Refractory metastatic breast cancer
  • HER2 Negative
  • MBC
  • ABC
  • Metastatic BC
  • Advanced BC
  • Unresectable BC
  • Refractory advanced breast cancer
  • Refractory ABC
  • Refractory MBC
  • HER3-DXd
  • estrogen receptor positive
  • progesterone receptor positive
  • ER+
  • PR+
  • ER+/PR+
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults with -confirmed negative, unresectable locally advanced or breast cancer that is hormone receptor positive (HR+) at the time of the first breast cancer diagnosis
  • Participants with a documented radiologic unresectable or metastatic progression
  • Participants may have received anthracyclines and taxanes as (neo) treatment and must have received one for Advanced breast cancer (ABC), but not more than one line. Participants must have a clinically or radiologically documented evidence of tumor progression on or after cyclin dependent kinase 4/6 (CDK 4/ 6) inhibitor combined with endocrine therapy. Previous treatments with PI3K inhibitors, mTOR inhibitors, AKT-inhibitors and poly ADP ribose polymerase (PARP)-inhibitors are allowed
  • Participants must have a tumor site easily accessible to (with exception of bone metastasis)
  • Participants must have at least one radiologically (different from the biopsy site)
  • Participants must have an PS equals to 0 or 1
  • Participants must have a of 12 weeks or more
  • Participants must have adequate bone marrow reserve and organ function, based on local laboratory data within 14 days prior to Cycle 1, Day 1
  • Female patients of reproductive/ must have a negative pregnancy test at screening (serum test within 14 days or urine test within 72 hours of enrollment). A positive urine pregnancy test result must be confirmed by a serum test. Patients must agree to use a highly effective form of or avoid intercourse during and upon completion of the study and for at least 7 months after the last dose of study drug.

The following contraception methods are considered highly effective:

  1. Hormonal or nonhormonal intrauterine device (IUD)
  2. Progestogen-only subdermal contraceptive implant
  3. Bilateral tubal occlusion
  4. Vasectomized partner
  5. Complete sexual abstinence defined as refraining from heterosexual intercourse during and upon completion of the study and for at least 7 months for females after the last dose of study drug.

Periodic abstinence (calendar, symptothermal, post-ovulation methods) is not an acceptable method of contraception. Penile/external condoms for male partners must be used in addition to the female patient's hormonal contraception for the duration treatment intervention and until 7 months following the last dose of trial intervention. Female patients must not donate, or retrieve for their own use, ova from the time of screening and throughout the study treatment period, and for at least 7 months after the final study drug administration.

  • A male participant capable of producing sperm is eligible to participate if he agrees to the following during the intervention period and for at least the time needed to eliminate each trial intervention. The length of time required to continue contraception after last dose for each trial intervention is 4 months. Avoid donating sperm. Note: Preservation of sperm should be considered prior to enrollment/randomization in this trial. Use a penile/external condom when having penile-vaginal intercourse with a nonparticipant of childbearing potential, PLUS partner use of an additional contraceptive method (see below), as a condom may break or leak:

    1. Progestogen-only contraceptive implant
    2. Hormonal or nonhormonal IUD
    3. Bilateral tubal occlusion (includes tubal ligation)
    4. Combined (estrogen- and progestogen-containing) hormonal contraception (oral, intravaginal, transdermal, injectable)
    5. Progestogen-only hormonal contraception (oral, injectable)
    6. Progesterone-only hormonal contraception where inhibition of ovulation is not the primary mode of action
    7. Cervical cap, diaphragm, or sponge with spermicide Contraceptive use should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

      If the contraception requirements in the local label for any of the trial interventions are more stringent than the requirements above, the local label requirements are to be followed. Note: If the participant is azoospermic (vasectomized or secondary to medical cause, documented from the site personnel's review of the participant's medical records, medical examination, or medical history interview), no contraception is required.

      Male participants must not freeze or donate sperm starting at screening and throughout the study period, and for at least 4 months after the final study drug administration

  • Participant must understand, sign, and date the written ICF prior to any protocol-specific procedures performed. Participant should be able and willing to comply with study visits and procedure as per protocol
  • Participant must be affiliated to a social security system or beneficiary of the same

Exclusion criteria

Exclusion Criteria:

  • Breast cancer amenable for resection or radiation therapy with curative intent
  • Any history of interstitial lung disease (ILD), actual ILD, or a suspicion of an ILD
  • Clinically severe pulmonary compromise (based on investigator's assessment) resulting from intercurrent pulmonary illnesses including, but not limited to:

    1. Any underlying pulmonary disorder
    2. Any , connective tissue or inflammatory disorder with pulmonary involvement
    3. OR prior pneumonectomy
  • The use of chronic systemic at a dose superior to 10 mg daily of prednisone or equivalent or any form of therapy prior to Cycle 1 Day 1. Participants who require use of bronchodilators, inhaled steroids, or local steroid injections may be included in the study
  • Evidence of any
  • Evidence of corneal disease
  • Any evidence of severe or uncontrolled systemic diseases including active bleeding diatheses, active infection, psychiatric illness/social situations, geographical factors, substance abuse, or other factors which in the investigator's opinion makes it undesirable for the participant to participate in the study or which would jeopardize compliance with the protocol
  • Evidence of clinically active spinal cord compression or defined as untreated and symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms
  • Exposure to prior systemic anticancer therapy (including agents) within 4 weeks or 5 half-lives (whichever is shorter) before enrollment.
  • Inadequate prior to Cycle 1 Day 1, defined as:

    1. Whole brain radiation therapy \<14 days or stereotactic brain radiation therapy \<7 days.
    2. therapy \<21 days
    3. Hormonal therapy \<21 days
    4. Major surgery (excluding placement of vascular access) \<28 days.
    5. Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation \<28 days or palliative radiation therapy \<14 days.
    6. Chloroquine or hydroxychloroquine ≤ 14 days
    7. \<28 days.
  • Prior treatment with an anti-HER3 antibody and/or ADC containing an exatecan derivative that is a topoisomerase I inhibitor
  • Participants with a grade equals or greater than 2 unresolved toxicities from previous anticancer therapy (other than alopecia)
  • A history of severe reactions to either the drug substances or inactive ingredients of U3-1402, or to other monoclonal antibodies
  • Any evidence of primary other than locally advanced or lung cancer within three years prior to Cycle 1 Day 1, except adequately resected non-melanoma skin cancer, curatively treated in-situ disease, or other solid tumors curatively treated
  • Uncontrolled or significant cardiovascular disease prior to Cycle 1 Day :

    1. interval higher than 470 ms for females and 450 ms for males according to Fridericia's formula (QTcF) and assessed based on triplicate ECGs, approximately 1 minute apart
    2. (LVEF) less than 50% by either ECHO or cardiac MRI or multigated acquisition scan (MUGA)
    3. Resting systolic blood pressure higher than 140 mmHg or diastolic blood pressure higher than 90 mmHg
    4. Myocardial infarction within six months
    5. Symptomatic congestive heart failure ( Classes 2 to 4 within 28 days before treatment)
    6. Uncontrolled angina pectoris within six months.
    7. Cardiac arrhythmia requiring antiarrhythmic treatment
  • Evidence of active or uncontrolled virus infection (HBV)

Participants are eligible:

  1. If HBsAg positive with chronic HBV infection (lasting 6 months or longer) and meet conditions below:

    • HBV DNA viral load \<2000 IU/mL
    • Start or maintain antiviral treatment if clinically indicated as per the investigator.
  2. Have normal transaminase values, or, if liver metastases are present, abnormal transaminases with a result of /ALT \<3 × , which are not attributable to HBV infection - Evidence of active or uncontrolled virus infection (HCV).

Participants are eligible if:

  1. History of hepatitis C infection eligible if the HCV viral load is below the level of detection in the absence of antiviral therapy during the previous 4 weeks
  2. Have normal transaminase values, or, if liver metastases are present, abnormal transaminases with a result of AST/ALT \< 3 × ULN, which are not attributable to HCV infection - Evidence of active or uncontrolled (HIV infection. Subjects must be tested for HIV viral load during the Screening Period if acceptable by local regulations or IRBs/IECs.

Participants are eligible if:

  1. ≥350 cells/mm3 at the time of screening 16
  2. Virologic suppression defined as confirmed HIV RNA level below 50 or the LLOQ (below the limit of detection) at the time of screening and for at least 12 weeks before screening
  3. No AIDS-defining opportunistic infections or conditions within the past 12 months
  4. On stable ART regimen, without changes in drugs or dose modification, for at least 4 weeks before trial entry (Day 1) and agree to continue ART throughout the trial.

    • Prior or ongoing illness, medical condition, surgical history, physical finding, or laboratory abnormality that, in the Investigator's judgment, could affect the safety of the subject; alter the absorption, distribution, metabolism or excretion of the study drug; or confound the assessment of study results.
    • Evidence of ongoing uncontrolled systemic bacterial, fungal, or viral infection. Subjects with localized fungal infections of skin or nails are eligible.
    • Female patient who is pregnant or breastfeeding or intends to become pregnant during the study.
    • Patient with any psychological, familial, sociological or geographical condition potentially hindering compliance with the study protocol procedures and follow-up schedule.
    • Patient under guardianship or deprived of his liberty by a judicial or administrative decision or incapable of giving its consent
    • Participation in another clinical trial evaluating an experimental drug (except non-interventional research
Terms in these criteria, in plain language(32)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
139 participants (estimated)

Study arms

  • Experimental
    U3-1402

    All participants enrolled in the study will receive U3-1402 at a dose of 5.6 mg/kg every 3 weeks until progression or until unacceptable toxicity

    Drug: U3-1402

Interventions

  • DrugPatritumab deruxtecanStudies of Patritumab deruxtecanPatritumab deruxtecan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    U3-1402 is uniquely designed to target HER3-a receptor that contributes to treatment resistance and poor prognosis in hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer patients. This drug is distinct from other interventions due to its composition as an antibody-drug conjugate (ADC): a monoclonal antibody against HER3 conjugated to a topoisomerase I inhibitor, which specifically targets HER3-overexpressing tumor cells. The drug is delivered via a cleavable linker that allows for controlled release of the chemotherapeutic agent within the cancer cells, minimizing systemic side effects.

    Also known as: HER3-DXd

06

What researchers measure

Primary outcomes

  1. Evaluation of objective response rate (ORR) based on investigator assessment

    Defined as the proportion of participants who achieved a confirmed complete response (CR) or partial response (PR) assessed by investigators

    Time frame: During treatment period, an average of 8 months

Secondary outcomes

  1. Evaluation of duration of response (DOR, investigator-assessed and as per retrospective central review)

    Applicable to participants with either complete response (CR) or partial response (PR) and is defined as the time from the first documented CR or PR until the date of disease progression, or until the date of death. It will be evaluated in the overall population and in subgroups of patients according to investigator assessment and as per retrospective central review

    Time frame: From cycle 3 (Week 6) up to 3 years after the EoT, an average of 42 months

  2. Evaluation of progression free Survival (PFS), investigator-assessed and as per retrospective central review

    Defined as the time date of the first dose until progression or death from any cause, whichever occurs first. It will be evaluated in the overall population according to investigator assessment and as per retrospective central review

    Time frame: From cycle 3 (Week 6) up to 3 years after the EoT, an average of 42 months

  3. Evaluation of clinical benefit ratio (CBR), investigator-assessed and as per retrospective central review

    Defined as the presence of at least a PR or CR, or a stable disease (SD) for more than six months under treatment. It will be evaluated in the overall population according to investigator assessment and as per retrospective central review

    Time frame: From cycle 3 (Week 6) up to 3 years after the EoT, an average of 42 months

  4. Percentage of patients experiencing adverse events

    Time frame: During treatment (at each cycle), at EoT and up to 47 days after EoT, an average of 9 months

  5. Frequency of treatment emergent adverse events (TEAEs) leading to change in treatment dose

    Time frame: During treatment, an average of 8 months

  6. Incidence of abnormal laboratory test results

    Time frame: During treatment (at each cycle) and at EoT an average of 8 months

  7. Incidence of abnormal ECG readings

    Time frame: During treatment and at EoT an average of 8 months

  8. Physical functioning sub-scale score of the European Organization for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ-C30) based on a scale from 1 to 4, where higher scores mean worse outcome

    Time frame: During treatment (Cycles 1, 2, 3 and then every 2 cycles), at EoT and then up to 3 years after EoT, an average of 42 months

  9. Changes in Eastern Cooperative Oncology Group performance status [ECOG PS] based on a score from 1 to 5, where higher scores mean worse outcomes

    Time frame: During treatment (at each cycle) and at EoT, an average of 8 months

  10. Change in left ventricular ejection fraction (LVEF)

    Time frame: During treatment and at EoT, an average of 8 months

  11. Global health sub-scale score of the European Organization for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ-C30) based on a scale from 1 to 7, where higher scores mean better outcome

    Time frame: During treatment (Cycles 1, 2, 3 and then every 2 cycles), at EoT and up to 3 years after EoT, an average of 42 months

  12. Severity of adverse events as assessed by CTCAE v5.

    Time frame: During treatment (at each cycle), at EoT and up to 47 days after EoT, an average of 9 months

  13. Objective response rate (ORR) as per central retrospective review

    Defined as the proportion of participants who achieved a confirmed complete response (CR) or partial response (PR) assessed by investigators and as per central retrospective review

    Time frame: During treatment period, an average of 8 months

  14. Overall survival (OS)

    Defined as the time from date of first dose until death. Patients alive at last follow-up will be censored at this date.

    Time frame: From C1D1 until death, an average of 42 months

07

Study locations

10 of 11 sites recruiting
08

References and documents

Publications

  • Pistilli B, Mosele F, Corcos N, Pierotti L, Pradat Y, Le Bescond L, Lacroix-Triki M, Nachabeh G, Alfaro A, Catelain C, Job B, Mami-Chouaib F, Badel S, Farace F, Oulhen M, Kannouche P, Tran DTN, Droin N, Vicier C, Frenel JS, D'Hondt V, Dalenc F, Bachelot T, Ducoulombier A, Benderra MA, Loirat D, Mayeur D, Deluche E, Deneuve J, Cheikh-Hussin R, Guyader P, Signolle N, Godefroy K, Talbot H, Vakalopoulou M, Christodoulidis S, Bernard E, Koudou Y, Sporchia A, Suto F, Li L, Sternberg DW, Michiels S, Andre F, Sellami D, Montagnac G. Patritumab deruxtecan in HR+HER2- advanced breast cancer: a phase 2 trial. Nat Med. 2025 Oct;31(10):3492-3503. doi: 10.1038/s41591-025-03885-3. Epub 2025 Sep 4. PubMed 40908353 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2021 (actual). Primary completion is estimated for Apr 2027, 71 months after the start.

Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's planned 71 months is above that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2021
First posted
Jul 16, 2021
StartActual
May 11, 2021
Primary completionEst.
Apr 11, 2027
CompletionEst.
Apr 11, 2030
Last update
Dec 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04965766
Collaborators
Daiichi Sankyo
Responsible party
Sponsor
First posted
Jul 16, 2021
Start date
May 11, 2021
Primary completion
Apr 11, 2027 (estimated)
Completion
Apr 11, 2030 (estimated)
Last update
Dec 23, 2025

Study contacts

Barbara PISTILLI, MD
Contact
barbara.pistilli@gustaveroussy.fr
+33 (0)1 42 11 42 11 ext. 61 62
Souad COSSÉ
Contact
souad.cosse@gustaveroussy.fr
+33 (0)1 42 11 42 11 ext. 62 48
Barbara PISTILLI, Dr
study director · Gustave Roussy, Cancer Campus, Grand Paris

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Patritumab deruxtecan

Start the discussion